Blog

Nov 27, 2019

Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now?

Posted by in categories: biotech/medical, genetics

Following strong results for its flagship CTX001 drug, should you add CRISPR to your portfolio?

Leave a reply